Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib | Zendy

Frankel Arthur E. | Zendy; Reddy Renuka | Zendy; DeSuza Kayla R. | Zendy; Deeb Khaled | Zendy; Carlin Aaron F. | Zendy; Smith Davey | Zendy; Xie Yushuang | Zendy; Naik Eknath | Zendy; Silver Richard T. | Zendy; Hasselbalch Hans C. | Zendy

Open Access

Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib

Author(s) -

Frankel Arthur E.,

Reddy Renuka,

DeSuza Kayla R.,

Deeb Khaled,

Carlin Aaron F.,

Smith Davey,

Xie Yushuang,

Naik Eknath,

Silver Richard T.,

Hasselbalch Hans C.

Publication year - 2021

Publication title -

clinical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.21

H-Index - 9

ISSN - 2050-0904

DOI - 10.1002/ccr3.3997

Subject(s) - ruxolitinib , medicine , myelofibrosis , asymptomatic , interferon , pegylated interferon , covid-19 , virology , immunology , ribavirin , gastroenterology , virus , bone marrow , hepatitis c virus , disease , infectious disease (medical specialty)

An 83‐year‐old female had asymptomatic SARS‐CoV‐2 infection while taking ruxolitinib. She remained RT‐PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID‐19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research